Particulars (Rs. in cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 1201.00 | 999.00 | 20.00% | 1088.00 | 10.45% |
EBITDA | 236.00 | 153.00 | 54.00% | 217.00 | 8.68% |
EBITDA Margin (%) | 19.60% | 15.32% | 428 bps | 20.00% | (40 bps) |
PAT | 94.00 | -149.00 | - | 68.00 | 37.11% |
EPS (Rs.) | 10.00 | -15.00 | - | 8.00 | 32.46% |
Source: Company Filings; stockaxis Research
Q2FY25 Result Highlights
Strides Pharma delivered stellar earnings growth for the quarter ended Q2FY25 driven
by strong performance in the US and turnaround in Stelis. Consolidated net sales
rose 20% YoY to Rs.1201.11 cr boosted by US and branded business in Africa. Gross
margins improved 270bps YoY to 61.3% driven by product mix. Consolidated EBITDA
witnessed its highest-ever numbers, recording a robust growth of 30% YoY to Rs.218
cr while EBITDA Margins expanded 210 bps at 19.6%. The share of losses from JV stood
at INR 118mn in Q1FY25 vs. a loss of INR 329mn in Q1FY25. Strides recorded a PAT
of Rs.68 cr against a loss of Rs.150 cr in Q2FY24.
US sales grew 7% QoQ (+26.2% YoY) to USD 75mn with growth driven by relaunching products from the government portfolio acquired from Endo.
Other regulated markets’ revenue increased by 6% YoY (flat QoQ) to Rs.346.4 cr. Growth markets grew 27% YoY to Rs.139.6 cr. Access market sales were down 4% YoY to Rs.84.8 cr.
Key Conference call takeaways
Guidance: i) Management expects US business to clock sales between USD 285–300mn
in FY25 while other segments shall grow alongside. (ii) Gross margins are likely
to range between 59–60% in line with industry standards, supported by better
operating leverage and continued free cash flow generation and EBITDA at USD 9.5–10bn
in FY25. (iii) It aims to repay Rs.500 cr of debt and bring debt to EBITDA within
2x (2.7x in FY24) (iv) EBITDA is expected to be around Rs.950 crores to Rs.1,000
crores (excluding OneSource this will be 750-800cr), (iv) Management expects 12-15%
growth in FY25.
Q2FY25 Overview
OneSource (formerly Stelis Biopharma):
International Markets
Product Approvals, Launches
Seasonality
Debt
Business Strategy
R&D
The company is investing in R&D for novel biologics and drug-device combinations,
with a focus on maintaining IP confidentiality.
Other key points:
The cash conversion cycle is 126 days as of 30th September 2024.
Strides Pharma delivered another impressive set of numbers for the quarter ended Q2FY25. We believe that The company is well-positioned to benefit from opportunities emerging in the global pharmaceutical market. The company derives a higher share of revenue from regulated markets, especially the U.S. Healthy growth in the base business in the U.S. and a strong product pipeline are expected to fuel the segment’s growth. Strides have a strong product pipeline, which is approved but yet to be commercialized and offers sizeable market opportunities. Moreover, the recent acquisition of the product portfolio from Endo Pharmaceuticals, including commercialized products, would add to the company’s product basket as well as diversify its portfolio across therapies and dosage forms. Growth prospects in other regulated markets are also likely to be better, led by product launches, increased market share, and portfolio optimization/maximization.
The emerging markets segment is expected to gain traction, backed by the likely revival of the institutional business and growth in the African business. The company is expected to continue to outperform in regulated markets, led by new launches like Icosapent and a healthy pipeline like Suprep in the U.S. region and increasing market share in the base portfolio. Further, better performance in Africa branded and the tender business (traction to build up in H2FY25) will also likely boost operating leverage. Management expects the performance to sweeten further in H2FY25 driven by US and access markets, which could also boost margins.
The company aims to launch 60 products in the next three years, which will help it scale up US revenues to USD 400mn. Strides is also working to improve its product offerings in US; from FY26 it aims to start filing for Control Substances Nasal Sprays and 505 (b)(2) products with the USFDA, which should drive growth beyond FY27E.The company maintained its EBITDA towards the higher end, driven by strong traction in the US region due to 1) New product launches in the regulated market 2) no price erosion pressure in the base portfolio, and. The company continues to control costs followed by a healthy product mix, which would aid the company to reach 20% EBITDA guidance by FY2025E. At CMP of Rs.1540, the stock is trading at 21x FY26E. We maintain HOLD rating on the stock.
Particulars (Rs. in cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 1201.00 | 999.00 | 20.00% | 1088.00 | 10.45% |
COGS | 498.00 | 418.00 | 19.00% | 420.00 | 18.43% |
Gross Profit | 703.00 | 581.00 | 21.00% | 667.00 | 5.42% |
Gross Margin (%) | 58.50% | 58.20% | 30 bps | 61.30% | (280 bps) |
Employee Benefit expenses | 219.00 | 200.00 | 10.00% | 212.00 | 3.42% |
Other expenses | 248.00 | 228.00 | 9.00% | 238.00 | 4.23% |
EBITDA | 236.00 | 153.00 | 54.00% | 217.00 | 8.68% |
EBITDA Margin (%) | 19.60% | 15.32% | 428 bps | 20.00% | (40 bps) |
Depreciation and amortization expenses | 51.00 | 60.00 | -16.00% | 49.00 | 3.97% |
EBIT | 185.00 | 93.00 | 99.00% | 168.00 | 10.03% |
Finance cost | 82.00 | 79.00 | 5.00% | 80.00 | 2.19% |
Other Income | 28.00 | 36.00 | -21.00% | 13.00 | 123.35% |
Profit before exceptional items and tax | 132.00 | 50.00 | 162.00% | 101.00 | 30.62% |
Exceptional items | -4.00 | -165.00 | - | -4.00 | 3.48% |
Profit before share of profit/loss of JV | 128.00 | -115.00 | - | 97.00 | 31.65% |
Share of loss of joint venture | -13.00 | -42.00 | - | -12.00 | 8.56% |
PBT | 115.00 | -157.00 | - | 85.00 | 34.86% |
Tax expenses | 21.00 | -7.00 | - | 17.00 | 26.00% |
PAT | 94.00 | -149.00 | - | 68.00 | 37.11% |
EPS (Rs.) | 10.00 | -15.00 | - | 8.00 | 32.46% |